At the news
? BEARISHIMPACT 5/10 DEF 14A filed Nov 10, 2026 at 16:05 ET
China Pharma Holdings filed its definitive proxy statement for the December 22, 2026 annual meeting. The meeting agenda includes the election of three independent directors, authorization of a reverse stock split of up to 1:50 to maintain NYSE American listing compliance, and a massive 14-fold increase in the share reserve under the 2010 Long-Term Incentive Plan from 569,600 to 8,603,800 shares. The company also discloses material related-party loans from Chairperson Zhilin Li totaling $1.78 million and a $1.88 million compensation payable balance.
- CEO/Chair Zhilin Li received $316,000 total compensation in FY2025, unchanged from FY2024.
- Board seeks authorization for a reverse stock split of up to 1:50 to address NYSE American low selling price compliance; a 1:10 reverse split was already completed on April 15, 2025.
- Proposal 3 seeks to increase the share reserve under the 2010 Long-Term Incentive Plan by 8,034,200 shares (from 569,600 to 8,603,800 shares), a roughly 14x increase.
- As of the record date, only 9,800 shares of restricted stock/options were outstanding and 559,800 shares remained available under the plan.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access